ABBV:NYE-AbbVie Inc.

EQUITY | Drug Manufacturers | New York Stock Exchange

Last Closing Price

USD 102.49

Change

+2.15 (+2.14)%

Market Cap

USD 163.62B

Volume

8.53M

Yahoo Analyst Target

USD 100.50 (-1.94%)

STA Analyst Target

USD 95.08 (-7.23%)
Yahoo Analyst Rating

Verdict

STA Analyst Rating

Verdict

STA Verdict

Verdict

About

AbbVie Inc is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a broad line of pharmaceutical products for treating chronic autoimmune diseases, virology and neurological disorders.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2018-01-16 )

Largest Industry Peers for Drug Manufacturers

Symbol Name Price(Change) Market Cap
JNJ Johnson & Johnson

+1.10 (+0.75%)

USD 394.54B
PFE Pfizer Inc.

+0.06 (+0.16%)

USD 218.16B
NVS Novartis AG

+0.08 (+0.09%)

USD 203.20B
MRK Merck & Company Inc. (new)

+3.41 (+5.81%)

USD 169.11B
SNY Sanofi American Depositary Sha..

+0.13 (+0.29%)

USD 113.03B
ABT Abbott Laboratories

-0.40 (-0.68%)

USD 101.72B
BMY Bristol-Myers Squibb Company

-2.89 (-4.60%)

USD 98.07B
GSK GlaxoSmithKline PLC

+0.42 (+1.12%)

USD 94.00B
LLY Eli Lilly and Company

-1.69 (-1.94%)

USD 93.91B
AZN Astrazeneca PLC

-0.66 (-1.85%)

USD 88.61B

ETFs Containing ABBV

FPX First Trust US Equity Opp.. 7.96 % 0.60 %

-0.51 (-0.34%)

USD 1.03B
FTXH First Trust Nasdaq Pharma.. 7.74 % 0.60 %

-0.24 (-0.34%)

USD 2.22M
ACT AdvisorShares Vice ETF 5.62 % 0.00 %

-0.09 (-0.34%)

USD 0.02B
BIBL Inspire 100 5.16 % 0.00 %

+0.04 (+-0.34%)

USD 8.13M
PJP PowerShares Dynamic Pharm.. 4.96 % 0.56 %

-0.32 (-0.34%)

USD 0.66B
PPH VanEck Vectors Pharmaceut.. 4.83 % 0.35 %

-0.10 (-0.34%)

USD 0.30B
HHL:CA Healthcare Leaders Income.. 4.82 % 1.37 %

-0.04 (-0.34%)

CAD 0.26B
XLV SPDR Select Sector Fund -.. 4.82 % 0.14 %

+0.43 (+-0.34%)

USD 17.56B
IYH iShares U.S. Healthcare 4.66 % 0.44 %

+0.62 (+-0.34%)

USD 2.04B
FHLC Fidelity MSCI Health Care.. 4.22 % 0.08 %

+0.09 (+-0.34%)

USD 0.97B
VHT Vanguard Health Care 4.00 % 0.10 %

+0.25 (+-0.34%)

USD 7.51B
LNGR Global X Longevity Themat.. 3.95 % 0.68 %

+0.07 (+-0.34%)

N/A
MPCT iShares MSCI Global Impac.. 3.72 % 0.49 %

+0.70 (+-0.34%)

USD 0.03B
DGRW WisdomTree U.S. Dividend .. 3.61 % 0.28 %

-0.13 (-0.34%)

USD 2.10B
IXJ iShares Global Healthcare 3.33 % 0.48 %

+0.06 (+-0.34%)

USD 1.70B
PXLG PowerShares Russell Top 2.. 3.28 % 0.39 %

-0.08 (-0.34%)

USD 0.20B
JHMH John Hancock Multifactor .. 3.15 % 0.50 %

+0.18 (+-0.34%)

USD 0.04B
QDYN FlexShares Quality Dynami.. 2.85 % 0.37 %

N/A

USD 0.06B
RNDV First Trust US Equity Div.. 2.79 % 0.00 %

+0.13 (+-0.34%)

USD 0.01B
SPDV AAM S&P 500 High Dividend.. 2.49 % 0.00 %

+0.11 (+-0.34%)

N/A
DQD:CA WisdomTree U.S. Quality D.. 2.48 % 0.58 %

N/A

CAD 0.02B
DGR:CA WisdomTree U.S. Quality D.. 2.48 % 0.47 %

+0.02 (+-0.34%)

CAD 0.02B
FDRR Fidelity Dividend ETF for.. 2.46 % 0.29 %

-0.10 (-0.34%)

USD 0.25B
JKD iShares Morningstar Large.. 2.36 % 0.20 %

-0.53 (-0.34%)

USD 1.04B
XBI SPDR Series Trust S&P Bio.. 2.19 % 0.35 %

-2.78 (-0.34%)

USD 4.61B
DTN WisdomTree U.S. Dividend .. 2.12 % 0.38 %

-0.43 (-0.34%)

USD 0.90B
ZUH:CA BMO Equal Weight US Healt.. 2.04 % 0.39 %

-0.18 (-0.34%)

CAD 0.31B
RYH Guggenheim S&P 500 Equal .. 1.81 % 0.40 %

+0.37 (+-0.34%)

USD 0.70B
PILL Direxion Daily Pharmaceut.. 1.78 % 0.00 %

-0.33 (-0.34%)

USD 3.19M
ZDY:CA BMO US Dividend ETF 1.75 % 0.33 %

-0.38 (-0.34%)

CAD 1.40B
FDMO Fidelity Momentum Factor 1.70 % 0.29 %

-0.07 (-0.34%)

USD 0.06B
FQAL Fidelity Quality Factor 1.58 % 0.29 %

-0.18 (-0.34%)

USD 0.05B
SPYD SPDR Series Trust Portfol.. 1.56 % 0.12 %

-0.23 (-0.34%)

USD 0.36B
CDL Compass EMP US Large Cap .. 1.43 % 0.35 %

-0.16 (-0.34%)

N/A
CATH Global X S&P 500 Catholic.. 1.39 % 0.29 %

-0.13 (-0.34%)

N/A
CVY Guggenheim Multi-Asset In.. 1.26 % 0.65 %

-0.14 (-0.34%)

USD 0.34B
DEF Guggenheim Defensive Equi.. 1.16 % 0.61 %

-0.05 (-0.34%)

USD 0.19B
FLQG Franklin LibertyQ Global .. 1.12 % 0.35 %

-0.04 (-0.34%)

USD 0.03B

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers)
Market Performance vs. Exchange (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 5.98% 70% C- 82% B-
Dividend Return 0.73% 100% A+ 67% D+
Total Return 6.71% 70% C- 85% B
Trailing 12 Months  
Capital Gain 65.33% 96% A 96% A
Dividend Return 4.24% 88% B+ 60% D-
Total Return 69.58% 96% A 96% A
Trailing 5 Years  
Capital Gain 188.38% 94% A 93% A
Dividend Return 29.35% 100% A+ 81% B-
Total Return 217.73% 94% A 94% A
Average Annual (5 Year Horizon)  
Capital Gain 15.84% 83% B 86% B
Dividend Return 19.53% 83% B 88% B+
Total Return 3.69% 88% B+ 63% D
Risk Return Profile  
Volatility (Standard Deviation) 18.45% 61% D- 41% F
Risk Adjusted Return 105.81% 96% A 82% B-
Market Capitalization 96.34B 82% B- 99% A+

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers)
Ratio vs. Market
(New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 16.30 48% F 32% F
Price/Book Ratio 27.26 9% F 2% F
Price / Cash Flow Ratio 5.19 35% F 21% F
Price/Free Cash Flow Ratio 19.30 65% D 36% F
Management Effectiveness  
Return on Equity 119.09% 96% A 98% A+
Return on Invested Capital 181.93% 100% A+ 99% A+
Return on Assets 9.94% 74% C 89% B+
Debt to Equity Ratio 33.00% 82% B- 75% C

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

High dividend returns

The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Low debt

The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.